Results Demonstrate that MGL-3196 Provides Metabolic, Anti-inflammatory and Anti-fibrotic Benefits in a Long-term, High Fat Diet, Mouse NASH Model
CONSHOHOCKEN, PA, USA I October 23, 2017 I Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL) today presented preclinical results for MGL-3196 in a poster session at The Liver Meeting® 2017, American Association for the Study of Liver Diseases (AASLD) being held at the Walter E. Washington Convention Center in Washington, DC, October 20 – 24, 2017.
MGL-3196 is a first-in-class, oral, once-daily, liver-directed, thyroid hormone receptor (THR) β-selective agonist medication that is in Phase 2 development as a treatment for non-alcoholic steatohepatitis (NASH) and heterozygous familial hypercholesterolemia (HeFH). Top-line results from the Phase 2 studies for NASH and HeFH are expected by year-end and in the first quarter of 2018, respectively.
Key findings from the long-term high fat diet (HFD) mouse NASH model include:
- confirmation that prolonged treatment of mice with HFD generates fatty liver disease with a liver gene array profile consistent with activation of NASH inflammation and fibrosis pathways
- findings that MGL-3196 potentially normalizes hepatic function in HFD animals, including restoration of normal hepatic metabolic regulation, liver size and histology without impacting tissues outside the liver
- apparent reversal and prevention of the progression of lipid, inflammatory and fibrotic markers of NASH at human equivalent exposures of MGL-3196
Poster # 1969: MGL-3196, a β-Selective Thyroid Hormone Receptor (THR) Agonist, Demonstrates Metabolic, Anti-inflammatory and Anti-fibrotic Benefits in a Long-term High Fat Diet (HFD) Mouse NASH Model
Rebecca Taub, John Franc, Martha Kelly, Madrigal Pharmaceuticals, Villanova, PA
http://www.madrigalpharma.com/wp-content/uploads/2017/10/AASLD_poster_1969_final2.pdf
To view additional upcoming and archived events and presentations, please go to http://www.madrigalpharma.com/newsroom/presentations/
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq:MGDL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company’s lead candidate, MGL-3196, is a first-in- class, orally administered, small-molecule, liver- directed, thyroid hormone receptor (THR) β-selective agonist that is currently in Phase 2 development for NASH and heterozygous familial hypercholesterolemia (HeFH). For more information, visit www.madrigalpharma.com.
SOURCE: Madrigal Pharmaceuticals
Post Views: 31
Results Demonstrate that MGL-3196 Provides Metabolic, Anti-inflammatory and Anti-fibrotic Benefits in a Long-term, High Fat Diet, Mouse NASH Model
CONSHOHOCKEN, PA, USA I October 23, 2017 I Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL) today presented preclinical results for MGL-3196 in a poster session at The Liver Meeting® 2017, American Association for the Study of Liver Diseases (AASLD) being held at the Walter E. Washington Convention Center in Washington, DC, October 20 – 24, 2017.
MGL-3196 is a first-in-class, oral, once-daily, liver-directed, thyroid hormone receptor (THR) β-selective agonist medication that is in Phase 2 development as a treatment for non-alcoholic steatohepatitis (NASH) and heterozygous familial hypercholesterolemia (HeFH). Top-line results from the Phase 2 studies for NASH and HeFH are expected by year-end and in the first quarter of 2018, respectively.
Key findings from the long-term high fat diet (HFD) mouse NASH model include:
- confirmation that prolonged treatment of mice with HFD generates fatty liver disease with a liver gene array profile consistent with activation of NASH inflammation and fibrosis pathways
- findings that MGL-3196 potentially normalizes hepatic function in HFD animals, including restoration of normal hepatic metabolic regulation, liver size and histology without impacting tissues outside the liver
- apparent reversal and prevention of the progression of lipid, inflammatory and fibrotic markers of NASH at human equivalent exposures of MGL-3196
Poster # 1969: MGL-3196, a β-Selective Thyroid Hormone Receptor (THR) Agonist, Demonstrates Metabolic, Anti-inflammatory and Anti-fibrotic Benefits in a Long-term High Fat Diet (HFD) Mouse NASH Model
Rebecca Taub, John Franc, Martha Kelly, Madrigal Pharmaceuticals, Villanova, PA
http://www.madrigalpharma.com/wp-content/uploads/2017/10/AASLD_poster_1969_final2.pdf
To view additional upcoming and archived events and presentations, please go to http://www.madrigalpharma.com/newsroom/presentations/
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq:MGDL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company’s lead candidate, MGL-3196, is a first-in- class, orally administered, small-molecule, liver- directed, thyroid hormone receptor (THR) β-selective agonist that is currently in Phase 2 development for NASH and heterozygous familial hypercholesterolemia (HeFH). For more information, visit www.madrigalpharma.com.
SOURCE: Madrigal Pharmaceuticals
Post Views: 31
